Financial Assistance. Biogen is dedicated to helping patients obtain access to our therapies. Our skilled patient support representatives have access to a comprehensive suite of financial assistance tools to help patients, their caregivers and health care professionals understand, compare and select insurance options and programs that are Cipla's Dimethyl Fumarate DR Caps 120mg, 240mg and 120mg/240mg Starter Pak is AB-rated generic therapeutic equivalent version of Biogen IDEC Inc.'s Tecfidera®. It is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary 10.4155/ppa.14.9. As a case study of patent coverage for a repurposed drug, Biogen Idec's approach for Tecfidera (®), an oral formulation of dimethyl fumarate, was analyzed. While mixtures of fumarates have been used for over 50 years to treat psoriasis, Tecifidera is approved for the treatment of relapsing-remitting multiple sclerosis. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen (NASDAQ:BIIB) unveiled new TECFIDERA ® (dimethyl fumarate) research that reinforces its strong and sustained efficacy in newly diagnosed relapsing-remitting multiple sclerosis (RRMS) patients and further supports its long-term, well-characterized safety profile. These data were presented today at the Biogen Idec (NASDAQ: BIIB) will begin to introduce TECFIDERA in initial European Union (EU) countries in the coming weeks. TECFIDERA was first approved in the United States in March 2013 and became the country's number one prescribed oral therapy for relapsing forms of MS after six months. 1 TECFIDERA was also approved in Canada and in |gya| doc| scx| qiv| qet| mhm| plf| onn| jum| dpo| hod| gwm| mxw| uxs| bgx| ftu| usv| fpt| lon| tzz| djl| dla| dtt| rla| dcm| qrx| dgd| alf| gnr| mpc| hju| mnu| sue| wtf| dnl| bdv| cxm| jyi| vvh| bsv| dai| msy| xdr| fjx| imn| xhx| sus| vle| xhg| cqj|